

SE♥UL M! SOUL

BIOTECH STARTUPS IN SEOUL



Nu Eyne Co., Ltd.

CEO

Dohyoung Kim

Tel

+82-2-2220-0691

Address

Unit 301 Samsung IT Valley, Seoul,
Republic of Korea

E-mail

Info@nueyne.com

Website

www.nueyne.com

Company profile

Nu Eyne is a South Korean MedTech R&D company that adopts the concept of Bioelectronic Medicine to treat various chronic diseases. The company researches and develops customized electrical stimulation protocols to control abnormal cellular activity in response to chronic diseases.

Product Introduction

A wearable treatment device for ADHD and ASD. By wearing the device for 8 hours roughly during sleep, the device transcutaneously delivers electrical stimulation on trigeminal nerves, and modulates the autonomic nervous system. It induces and maintains sleep. The device is currently in clinical investigation with ASD.





Coagulant Therapeutics

CEO

Terry Hermiston

Tel

+82-10-2496-4795

Address

10F, 704, Seolleung-ro, Gangnam-gu,
Seoul, Republic of Korea

E-mail

thermiston@coagulanttherapeutics.com


Website

www.coagulanttherapeutics.com

Company profile

Leveraging 100+ years of collective experience and leveraging assets including over 30 patents acquired from Bayer AG and Maxygen, Coagulant Therapeutics has developed an optimized and proprietary rFVIIa molecule, termed CT-001, for the safe and effective pharmaceutical intervention for the treatment of acute bleeding.

Product Introduction



[CT-001 – A Novel Factor VIIa]

Building on the proven clinical activity of FVIIa to stop bleeds, we engineered FVIIa to both enhance its activity and engineered in additional safety measures to ensure the balance of enhanced potency with increased safety for acute bleeding. A highly potent and safe FVIIa approach for a large potential patient population.



HAI Inc.

CEO

Jinwoo Kim

Tel

+82-2-313-1236

Address

HAI, 5F Room 501, 428, Sami-daero,
Jongno-gu, Seoul, Republic of Korea

E-mail

contact@hii.io


Website

hii.co.kr

Company profile


HAI is developing innovative digital health solutions in the diagnosis and treatment of central nervous system diseases such as mild cognitive impairment and dysarthria after stroke. HAI strives to overcome the limitations of previous medicines and drugs using digital technologies. We are developing digital health solutions based on strong empirical evidence and clinical validation. This digital health solutions do not inject medicine directly into the body and is therefore relatively low risk high efficacy compared to previous treatments.

Product Introduction



Alzguard

Alzguard is a system that can detect signs of cognitive decline. Our advantage is to utilize artificial intelligence technology in providing accurate assessment and customized treatment by using digital biomarkers on users' smartphone without any other cumbersome equipments.



Anzeilax

Anzeilax app is a digital therapeutics designed to enhance psychological flexibility on a various emotional events of patients with Generalized Anxiety Disorder (GAD). Anzeilax provides Acceptance and Commitment Therapy (ACT) and self-affirmation, which are adapted onto a self-talk method via smartphone.



Repeech

Repeech provides voice data-based precise assessment and personalized treatment for dysarthria patients on a single mobile device.



ForMe

ForMe is a voice companion agent for enhancing the executive function of ADHD children.

TWINPIG BIOLAB Inc.

CEO

Moonkyu Kang, Ph. D.

Tel

+82-2-964-7770

Address

Rm 607, SEOUL BIOHUB, 23 Kyungheedaero,
Dongdaemun-gu, Seoul, Republic of Korea

E-mail

BD@twinpigbio.com


Website

www.twinpigbio.com

Company profile

Twinpig Biolab, Inc. (Twinpig Biolab) is a technology focused bio-venture, which develops next generation new drug as establishing intellectual properties based on Industry-Academy-Institute cooperation and network of R&D. Twinpig Biolab was established in 2019 after ending of basic researches for 12 years from starting of anti-cancer immunotherapeutics in 2007 as university-centered researches. Twinpig Biolab is having patents for major materials and technologies of anti-cancer immunotherapeutics and selected for TIPS by Ministry of SMEs and Startups in 2020. In addition, by attracting various investments, we are envisioning global clinical trials for development of anti-cancer immunotherapeutics. Through this, technology export and collaboration with global pharmaceutical companies are underway and the goal of our company is to save the lives of cancer patients, resulting in lead them to lead humane lives through development of anti-cancer immunotherapeutics.

Product Introduction



First in Class drug, TB511, which eliminates M2-TAM in tumor microenvironment, resulting in cancer killing

- ▶ TB511 is a Dual Peptide conjugate of TAMpep-d(KLA)2.
- ▶ MoA: TAMpep binds to CD1010 (code name) on TAM → Endocytosis → d(KLA)2 disrupts mitochondrial membrane → TAM apoptosis.
- ▶ By eliminating M2 TAMs in TME, tumors are more accessible for immune



CELLnLIFE Inc.

CEO

Myoung Woo Lee

Tel

+82-2-6082-3930

Address

Room 803, 50 Digital-ro 33-gil, Guro-gu,
Seoul, Republic of Korea

E-mail

mwlee@cellnlife.com

Website

www.cellnlife.com

Company profile

CELLnLIFE Inc. is a company that develops immune disease treatments using IntenCell®, an efficacy-enhancing stem cell. Based on the independently developed S-I-S culture platform technology, we are striving to overcome therapeutic efficiency limitations of stem cell therapy, thereby delivering healthy life and wellness to suffering patients with unmet medical needs.

We are constantly challenging ourselves and do our best to grow into a company that can lead the global stem cell therapy market, while maintaining strong corporate ethics.

Product Introduction



IntenCell®: Total Solution of Cell Therapy

Developed based on our proprietary technology, IntenCell® is a therapeutic agent with excellent immunosuppression, inflammation control, and regenerative capabilities. A key characteristic of IntenCell® is its immediate therapeutic efficacy, without toxicity or side effects. IntenCell® is mesenchymal stem cells derived from umbilical cord and overcomes current limitations like shortage of donors and tissues, insufficient number of cells and heterogeneic cells.

► Indication: SR-aGvHD, liver cirrhosis



NeuroVenti

CEO

Chan Young Shin, Dong-churl Seo

Tel

+82-2-540-5630

Address

4th, 15, Seolleung-ro 121-gil, Gangnam-gu, Seoul, Republic of Korea

E-mail

contact@neuroventi.com

Website

www.neuroventi.com

Company profile

NeuroVenti is a biotech startup developing small molecule drugs against neurodevelopmental disorders including autism spectrum disorder which also can be used against syndromic ASD like fragile X syndrome. Also, we offer CDRO services for efficacy and safety assessment for CNS drug candidates.

Product Introduction

NV01-A02

NV01-A02 is multi-target autism drug candidate, selective regulator of serotonin and dopamine receptors responsible for the modulation of social interaction. It is approved as an orphan drug designation for FXS by US FDA on Oct, 2022. It will be applied for phase II clinical trials (Korea) in 2023.

NV01-A02

ASD drug candidates
Multi-target action
ODD designation (FDA)
Entering phase II trial '23

CDRO Biz


· in vitro/in vivo efficacy in CNS
· Side effect & addiction verification

NV01-E01

· e-TNS electroceuticals
· Under phase II trial (Kr)
· Commercialize '25

NV01-A03, 062

· Depression, ASD and FXS
· Empowered portfolio





UIMD Inc.

CEO

Young Deuk Lee

Tel

+82-2-3478-1587

Address

#509 15 Mallijae-ro, Mapo-gu, Seoul,
Republic of Korea

E-mail

uimd@uimd.kr

Website

www.uimd.co.kr

Company profile

UIMD aims to be a game changer in digital morphology of “Peripheral Blood Image Analysis” and “Bone Marrow Image Analysis” by pioneering and leading a new platform for in vitro diagnostic medical devices based on artificial intelligence.

Product Introduction



Clear cell images of peripheral blood & bone marrow are acquired from a smeared slide, and the cell morphology of individual cell is analyzed using state-of-the-art artificial intelligence algorithms. The image analyzer can overcome many limitations manual cell differentials present in today's fast-paced medical field.

HUINNO

HUINNO

CEO

Yeongjoon Gil

Tel

+82-2-2151-3161

Address

Rain Avenue 3,4,5F,19, Apgujeong-ro
79-gil, Gangnam-gu, Seoul, Republic of
Korea

E-mail

jmshim@hainno.com

Website

www.huinno.com

Company profile

Huinno is an AI-powered RPM platform company, headquartered in Seoul, Korea.

We provide medical-grade arrhythmia detection solutions with our award-winning MEMO AI and MEMO Platform.

Product Introduction



- ▶ MEMO Platform is comprised of a configurable set of multi-parameter devices and advanced diagnostic services with continuous vital sign monitoring.
- ▶ MEMO Patch is an ECG monitor that automatically detects arrhythmia with an edge-computing technology and to send alerts even in network-disconnected situations.
- ▶ MEMO Care is analytics-streaming dashboard powered by the MEMO AI algorithm.



D&P Biotech Inc.

CEO

Myunghoon Lee

Tel

+82-2-786-5577

Address

92, Beobwon-ro, Songpa-gu, Seoul,
Republic of Korea

E-mail

lmhoon@dnpbitech.com

Website

www.dnpbiotech.com

Company profile

D&P Biotech is a biomarker specialist company with key technologies in lung cancer prognostic genomic diagnosis, premature birth microbiome diagnosis, and normal pressure hydrocephalus (NPH) screening diagnosis biomarkers, and pursue innovative technology development that have not yet been commercialized.

Product Introduction



Healthy Bebe Quantification kit performs quantitative analysis by amplifying six highly specific microorganisms present in female vaginal or cervical secretion samples using multiplexing qPCR. We aim to prevent, treat, and manage the risk of premature birth by predicting the risk of premature birth.



QGENETICS Co., Ltd.

CEO

CHANG MUN SEOG

Tel

+82-2-6348-9440

Address

#504, Seoul Industry-Academia Bio Center, Kyunghee University, 23, Kyungheedae-ro, Dongdaemun-gu, Seoul, Republic of Korea

E-mail

qgenetics@qgenetics.co.kr


Website

www.qgenetics.co.kr

Company profile

Qgenetics is a innovative new drug R&D start-up venture company which has strong strenths specialized in mesenchymal stem cell differentiation, and has researched and developed new drug candidates for the treatment of metabolic diseases such as osteoporosis and obesity. We invented and has QG3030, chemical compound, with high efficacy and a new mechanism of action in order to develop a theraeutic agent for diseases with medical unment needs and high market demand. We are achieving the development of a treatment for osteoporosis as our primary goal, and we are continuously expanding and developing treatments area for obesity, osteoarthritis, sarcopenia, and cachexia.

Product Introduction



We have completed non-clinical research (toxicity, efficacy, mechanism of action, etc.) and CMC (chemical, manufacturing and control) process development for QG3030, which has a mechanism to treat osteoporosis by promoting the differentiation of mesenchymal stem cells and activating osteoblasts. Clinical phase I study design is in progress. In addition, QG3030 presents a new area of research and development for osteoporosis treatment by binding with a new target molecules in mesenchymal stem cells other than the target molecule of the existing osteoporosis treatment.

SE♥UL
M!SOUL
BIOTECH STARTUPS IN SEOUL

invest
Seoul

biohub

SEOUL BIO HUB